Lead Product(s) : Elsubrutinib,Upadacitinib
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of systemic lupus erythematosus.
Brand Name : ABBV-599
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2023
Lead Product(s) : Elsubrutinib,Upadacitinib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Upadacitinib,Elsubrutinib
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
Details : ABBV-599 is a combination of upadacitinib, a JAK inhibitor and elsubrutinib a bruton tyrosine kinase inhibitor which is being investigated for the treatment of systemic lupus erythematosus.
Brand Name : ABBV-599
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 23, 2023
Lead Product(s) : Upadacitinib,Elsubrutinib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?